Tag Archives: Liana Moussatos

Wedbush Reiterates a Buy Rating on Clearside Biomedical (CLSD)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $4. The company’s shares closed yesterday at $1, close to its 52-week low of $0.95. According to TipRanks.com,

ObsEva SA (OBSV) Received its Third Buy in a Row

After H.C. Wainwright and Credit Suisse gave ObsEva SA (NASDAQ: OBSV) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on ObsEva SA today and set a price

Wedbush Keeps Their Buy Rating on Xoma Corp (XOMA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Xoma Corp (XOMA – Research Report), with a price target of $25. The company’s shares closed yesterday at $15.99. According to TipRanks.com, Moussatos ‘ ranking currently

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clearside Biomedical (NASDAQ: CLSD), Acceleron Pharma (NASDAQ: XLRN) and Regeneron (NASDAQ: REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clearside Biomedical (CLSD – Research Report), Acceleron Pharma (XLRN – Research Report) and Regeneron (REGN – Research Report). Clearside Biomedical (CLSD) Wedbush analyst Liana Moussatos

Xoma Corp (XOMA) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Xoma Corp (XOMA – Research Report) today and set a price target of $25. The company’s shares opened today at $18.26. According to TipRanks.com, Moussatos is currently ranked with no stars

Wedbush Reiterates Their Buy Rating on United Therapeutics (UTHR)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics (UTHR – Research Report), with a price target of $273. The company’s shares opened today at $81.29, close to its 52-week low of $74.31.